Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ab Corporate Bond ETF (EYEG)

Ab Corporate Bond ETF (EYEG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family AllianceBernstein
  • Assets Under Management 25,014,500
  • Shares Outstanding, K 700
  • 60-Month Beta N/A
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 1.60 (4.48%)
  • Most Recent Dividend 0.152 on 11/01/24
  • Management Fee 0.30%
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.60 +1.38%
on 11/06/24
36.11 -0.06%
on 11/08/24
+0.11 (+0.31%)
since 10/25/24
3-Month
35.60 +1.38%
on 11/06/24
37.24 -3.09%
on 09/18/24
-0.64 (-1.74%)
since 08/23/24

Most Recent Stories

More News
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate...

KPRX : 3.32 (-1.45%)
EYEG : 36.09 (+0.99%)
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and...

EYEG : 36.09 (+0.99%)
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-

EYEG : 36.09 (+0.99%)
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products...

EYEG : 36.09 (+0.99%)
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...

EYEG : 36.09 (+0.99%)
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...

EYEG : 36.09 (+0.99%)
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform-

EYEG : 36.09 (+0.99%)
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study

- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021-

EYEG : 36.09 (+0.99%)
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-

EYEG : 36.09 (+0.99%)
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory...

EYEG : 36.09 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Fund Summary

The AB Corporate Bond ETF seeks to maximize total return through current income and long-term capital appreciation.

See More

Top 10 Holdings

Name % Holdings
ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 1.77%
US DOLLAR 0.56%
GEORGIA PACIFIC LLC SR UNSECURED 144A 05/26 0.95 0.51%
INTEL CORP SR UNSECURED 05/26 2.6 0.51%
HCA INC COMPANY GUAR 09/26 5.375 0.51%
CAPITAL ONE FINANCIAL CO SUBORDINATED 07/32 VAR 0.51%
CROWN CASTLE INC SR UNSECURED 07/26 1.05 0.51%
FIDELITY NATL INFO SERV SR UNSECURED 03/26 1.15 0.51%
IBM CORP SR UNSECURED 05/27 1.7 0.50%
BANK OF AMERICA CORP SR UNSECURED 03/27 VAR 0.50%

See More

Key Turning Points

3rd Resistance Point 36.20
2nd Resistance Point 36.14
1st Resistance Point 36.12
Last Price 36.09
1st Support Level 36.04
2nd Support Level 35.98
3rd Support Level 35.96

See More

52-Week High 37.24
Fibonacci 61.8% 36.20
Last Price 36.09
Fibonacci 50% 35.88
Fibonacci 38.2% 35.56
52-Week Low 34.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar